Patient reactions to personalized medicine vignettes: An experimental design

Abstract

Purpose Translational investigation on personalized medicine is in its infancy. Exploratory studies reveal attitudinal barriers to “race-based medicine” and cautious optimism regarding genetically personalized medicine. This study describes patient responses to hypothetical conventional, race-based, or genetically personalized medicine prescriptions. Methods Three hundred eighty-seven participants (mean age = 47 years; 46% white) recruited from a Baltimore outpatient center were randomized to this vignette-based experimental study. They were asked to imagine a doctor diagnosing a condition and prescribing them one of three medications. The outcomes are emotional response to vignette, belief in vignette medication efficacy, experience of respect, trust in the vignette physician, and adherence intention. Results Race-based medicine vignettes were appraised more negatively than conventional vignettes across the board (Cohen’s d = −0.51−0.57−0.64, P < 0.001). Participants rated genetically personalized comparably with conventional medicine (− 0.14−0.15−0.17, P = 0.47), with the exception of reduced adherence intention to genetically personalized medicine (Cohen’s d = −0.38−0.41−0.44, P = 0.009). This relative reluctance to take genetically personalized medicine was pronounced for racial minorities (Cohen’s d =−0.38−0.31−0.25, P = 0.02) and was related to trust in the vignette physician (change in R2 = 0.23, P < 0.001). Conclusions This study demonstrates a relative reluctance to embrace personalized medicine technology, especially among racial minorities, and highlights enhancement of adherence through improved doctor-patient relationships.

Attitudes of African Americans Toward Return of Results From Exome and Whole Genome Sequencing

“…Consistent with a broader range of expected risks and benefits, for some AAs, a providermanaged and -driven model for returning results may be unacceptable or less effective [Butrick et al, 2011]. AA participants shared stories about negative health care experiences that stress the importance of maintaining control over the receipt of results.…”

Racial minority group interest in direct-to-consumer genetic testing: findings from the PGen study

“…Rahm et al examined perceptions of DTC-PGT advertising among various demographic groups and reported that individuals from minority groups may not consider genetic knowledge to be as empowering as Whites (Rahm et al 2012). One vignette-based study found that minority groups were more likely to report reluctance to adhere to medical prescriptions based on genetics compared to conventional prescriptions (Butrick et al 2011). While racial differences in knowledge/interest in genetic testing have been reported (Mai et al 2014;Pagan et al 2009 (Catz et al 2005).…”

An Index of Barriers for the Implementation of Personalised Medicine and Pharmacogenomics in Europe

“…In summary, health literacy needs to be increased by clear communication channels to adjust the public's expectations and information about biomarkers (including genomic assays). Besides the utility of CDx, concerns on privacy regulations and genetic discrimination that exist among the public should be reduced [3,25,61,62,63,64,65]. Within the communication to patients, the legislation for privacy concerning genomic information has to be stated clearly [2].…”